Soufflé Raises $135M for RNA Therapies

Soufflé Therapeutics has raised $135 million to advance RNA medicines that depend on getting therapeutic molecules into hard-to-reach tissues such as muscle and heart.

What happened

The Boston-based company closed an oversubscribed Series B led by Juvia Group, with participation from new and existing investors including TCG Crossover Management, BB Biotech, Fidelity, Amgen Ventures, ARCH Venture Partners, Bessemer Venture Partners and Temasek. Soufflé is developing a platform called REMEDY, or Receptor Mediated Delivery, which is designed to identify receptors on specific cells and use them to transport RNA-based treatments into those cells. Its lead programmes target facioscapulohumeral muscular dystrophy and heart failure. The funding will support first-in-human studies and additional preclinical work. These programmes remain investigational, and neither safety nor efficacy has been established in patients.

Why it matters

A major constraint in RNA therapeutics is delivery. Many approaches work best in the liver, while muscle, heart and other tissues remain harder to target efficiently. If Soufflé can demonstrate reliable cell-selective delivery, the same platform could support multiple drug programmes rather than a single asset.

The bigger picture

Investor interest is increasingly shifting from RNA payload design alone toward the delivery systems that determine whether medicines reach the right tissue. Clinical data will decide whether Soufflé's platform becomes a broadly useful therapeutic technology or remains promising preclinical science.